Project Grant R21CA282484
Award Date
9/19/23
Completion Date
8/31/25
Dollars Obligated
$402K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
The University of Louisville Office of Research & Innovation has been awarded a $402,401 Project Grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393). The grant will fund the development and investigation of a lung cancer vaccine based on exosomes derived from induced pluripotent stem cells (iPSCs) expressing the immunostimulatory cytokine GM-CSF (iPSC-EXO). The research aims to prevent lung tumorigenesis by triggering CD8+ T cell-mediated...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a new monoclonal antibody-based therapeutic tool to treat small cell lung cancer (SCLC). The $194,013 award to the University of Southern California will fund two key objectives: 1) generation of a mouse monoclonal antibody specifically targeting an abnormal isoaspartylated form of the ELAVL4 protein found on SCLC tumors, and 2) testing the therapeutic efficacy of this antibody...
The National Cancer Institute (NCI) awarded a $1,506,651 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University (VCU) on July 18, 2024. The project aims to evaluate a new agent called PEPDG278D for overcoming drug resistance in non-small cell lung cancer (NSCLC). PEPDG278D is a recombinant human protein that induces the degradation of the oncogenic drivers EGFR and HER2, which are frequently overexpressed or mutated in NSCLC. The project will assess...
The National Cancer Institute (NCI) awarded a $158,365 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of North Carolina at Chapel Hill (UNC-CH) to conduct research on the impact of NRF2 signaling activation on lung squamous cell carcinoma (LUSC) development and the tumor microenvironment. The project aims to develop a novel genetically-engineered mouse model to test how activated NRF2 affects LUSC incidence, tumor characteristics, gene/protein expression, and the...
The federal Project Grant award R01CA297605, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program, supports research to develop a novel therapeutic targeting LCN2, a protein that suppresses anti-tumor immune responses, for the treatment of KRAS-driven non-small cell lung cancer (NSCLC). The $696,569 award to New York University will fund a 5-year project to: 1) characterize the impact of LCN2 on the tumor microenvironment, 2) develop...
The National Cancer Institute (NCI) awarded a $234,749 Project Grant under CFDA 93.395 (Cancer Treatment Research) to The Ohio State University to investigate the role of hedgehog signaling in tumor-associated macrophages and its impact on CD8+ T cell recruitment and anti-tumor immune responses in non-small cell lung cancer (NSCLC). The 2-year project aims to study the effects of combining a hedgehog inhibitor (vismodegib) with an anti-PD-L1 therapy (atezolizumab) in a Phase Ib clinical trial...
The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Louisville in the amount of $234,889 to fund research aimed at developing a novel immunotherapy regimen for prostate cancer. The research project, titled "Guadecitabine-Directed Immune Regulation in Targeting Prostate Cancer," seeks to investigate how the epigenetic modulator guadecitabine can enhance antigen presentation and increase prostate...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $1,130,538.00 to the University of Louisville to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key focus is on investigating the cancer-specific expression of the Tn antigen and its role in PDAC progression, metastasis, and survival. The research aims to determine the mechanisms by which the Tn antigen enhances PDAC, identify...
The National Cancer Institute (NCI) awarded PDX Pharmaceuticals Inc. a $321,304 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance the commercialization readiness of their nanoparticle-based immunotherapy for non-small cell lung cancer (NSCLC) treatment. The grant supports two key activities: 1) Pursuing international patent protection for PDX's core nanoparticle delivery platform (PDX-NP) and lead candidate ARAC-02 immunotherapy, and 2) Initiating...
This $641,336 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Ohio State University aims to advance immunotherapy for non-small cell lung cancer (NSCLC). The project will investigate how disrupting the GARP-TGFbeta axis in the tumor microenvironment using the anti-GARP antibody PIIO-1 can enhance CD8+ T cell function and overcome resistance to immune checkpoint blockade therapy in NSCLC patients. Key objectives include defining how GARP...